These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1498901)

  • 21. Brofaromine versus imipramine in in-patients with major depression--a controlled trial.
    Volz HP; Gleiter CH; Möller HJ
    J Affect Disord; 1997 Jul; 44(2-3):91-9. PubMed ID: 9241569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.
    van Vliet IM; den Boer JA; Westenberg HG
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):21-9. PubMed ID: 1638170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
    van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brofaromine--a review of its pharmacological properties and therapeutic use.
    Volz HP; Gleiter CH; Waldmeier PC; Struck M; Möller HJ
    J Neural Transm (Vienna); 1996; 103(1-2):217-45. PubMed ID: 9026374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study.
    Lott M; Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Katz RJ; Schaettle SC
    J Clin Psychopharmacol; 1997 Aug; 17(4):255-60. PubMed ID: 9241003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacology of reversible MAO-A inhibitors.
    Bieck PR; Antonin KH; Schmidt E
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():345A-346A. PubMed ID: 1498864
    [No Abstract]   [Full Text] [Related]  

  • 27. Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients.
    Hoencamp E; Haffmans PM; Dijken WA; Hoogduin CA; Nolen WA; van Dyck R
    J Affect Disord; 1994 Mar; 30(3):219-27. PubMed ID: 8006248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia.
    Bakish D
    J Clin Psychopharmacol; 1994 Feb; 14(1):74-5. PubMed ID: 8151007
    [No Abstract]   [Full Text] [Related]  

  • 29. A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression.
    Bakish D; Wiens A; Ellis J; Alda M; Lapierre Y
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():12-7. PubMed ID: 1394026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brofaromine vs. maprotiline plus lithium in treatment-resistant depressed outpatients.
    Hoencamp E; Haffmans PM
    Psychiatry Res; 1991 Mar; 36(3):333-5. PubMed ID: 2062972
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks.
    Volz HP; Müller H; Sturm Y; Preussler B; Möller HJ
    Psychiatry Res; 1995 Sep; 58(2):107-15. PubMed ID: 8570762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic.
    Katz RJ; Lott MH; Arbus P; Crocq L; Herlobsen P; Lingjaerde O; Lopez G; Loughrey GC; MacFarlane DJ; McIvor R
    Anxiety; 1994-1995; 1(4):169-74. PubMed ID: 9160569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD
    J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical depression. A valid clinical entity?
    Stewart JW; McGrath PJ; Rabkin JG; Quitkin FM
    Psychiatr Clin North Am; 1993 Sep; 16(3):479-95. PubMed ID: 8415233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
    Celada P; Pérez J; Alvarez E; Artigas F
    J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression.
    De Wilde JE; Geerts S; Van Dorpe J; Bruhwyler J; Géczy J
    Acta Psychiatr Scand; 1996 Dec; 94(6):404-10. PubMed ID: 9020990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.
    Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC
    Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa.
    Davis BA; Kennedy SH; D'Souza J; Durden DA; Goldbloom DS; Boulton AA
    J Psychiatry Neurosci; 1994 Jul; 19(4):282-8. PubMed ID: 7918350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability and efficacy of high-dose moclobemide alone and in combination with lithium and trazodone.
    Magder DM; Aleksic I; Kennedy SH
    J Clin Psychopharmacol; 2000 Jun; 20(3):394-5. PubMed ID: 10831036
    [No Abstract]   [Full Text] [Related]  

  • 40. Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression.
    Steiger A; Holsboer F; Gerken A; Demisch L; Benkert O
    Pharmacopsychiatry; 1987 Nov; 20(6):262-9. PubMed ID: 3432361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.